These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9443422)

  • 1. Monitoring platelet GP IIb/IIIa antagonist therapy.
    Coller BS
    Circulation; 1998 Jan 6-13; 97(1):5-9. PubMed ID: 9443422
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.
    Coller BS
    Circulation; 1997 Dec; 96(11):3828-32. PubMed ID: 9403602
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
    Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H
    Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Kleiman NS
    Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
    Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
    Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ; Runyon JP; Kleiman NS; Higby NA; Anderson LC; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1996 Sep; 94(5):906-10. PubMed ID: 8790024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?
    Kereiakes DJ
    Am Heart J; 1999 Jul; 138(1 Pt 2):S39-46. PubMed ID: 10385790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for intracoronary administration of abciximab.
    Romagnoli E; Burzotta F; Trani C; Biondi-Zoccai GG; Giannico F; Crea F
    J Thromb Thrombolysis; 2007 Feb; 23(1):57-63. PubMed ID: 17160551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
    Aylward P
    Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
    Roffi M; Mukherjee D
    Eur Heart J; 2008 Feb; 29(4):429-31. PubMed ID: 18276614
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS; Lang D; Scudder LE
    Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
    Simon DI; Liu CB; Ganz P; Kirshenbaum JM; Piana RN; Rogers C; Selwyn AP; Popma JJ
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R; Glick HA; Herrmann HC; Kimmel SE
    J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
    Roffi M; Mukherjee D; Chew DP; Bhatt DL; Cho L; Robbins MA; Ziada KM; Brennan DM; Ellis SG; Topol EJ
    Circulation; 2002 Dec; 106(24):3063-7. PubMed ID: 12473552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.